Comparative Pharmacology
Head-to-head clinical analysis: DETROL LA versus SANCTURA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DETROL LA versus SANCTURA.
DETROL LA vs SANCTURA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tolterodine is a competitive muscarinic receptor antagonist. It blocks acetylcholine binding at muscarinic receptors (M1–M5), reducing detrusor muscle contraction and bladder pressure, thereby increasing bladder capacity and decreasing urinary frequency.
Trospium chloride is an antimuscarinic agent that competitively inhibits acetylcholine at muscarinic receptors, thereby reducing detrusor muscle contractions and increasing bladder capacity.
4 mg orally once daily; may be reduced to 2 mg once daily based on tolerability.
20 mg orally twice daily, with or without food. Maximum dose 20 mg twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 7 hours (range 5-10 hours) for the extended-release formulation, allowing once-daily dosing.
Terminal elimination half-life is approximately 12–20 hours in healthy adults, allowing twice-daily dosing.
Approximately 77% eliminated in urine (primarily as metabolites, <1% unchanged) and 17% in feces.
Primarily renal (approximately 60% as unchanged drug and metabolites); biliary/fecal elimination accounts for ~30%.
Category C
Category C
Anticholinergic
Anticholinergic